647 related articles for article (PubMed ID: 26799840)
1. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
Perez F; El Chakhtoura NG; Papp-Wallace KM; Wilson BM; Bonomo RA
Expert Opin Pharmacother; 2016; 17(6):761-81. PubMed ID: 26799840
[TBL] [Abstract][Full Text] [Related]
2. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
3. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
Zhang H; Liang B; Wang J; Cai Y
Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
Chiotos K; Hayes M; Gerber JS; Tamma PD
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226
[TBL] [Abstract][Full Text] [Related]
5. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text]